Instil Bio, Inc. General and Administrative Expense
Instil Bio, Inc. (TIL) reported General and Administrative Expense of $5.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GeneralAndAdministrativeExpense · last filed 2026-08-13
- Instil Bio, Inc. general and administrative expense for the quarter ending 2026-06-30 was $5.13M, a 16.68% decline year-over-year.
- Instil Bio, Inc. general and administrative expense for the quarter ending 2026-03-31 was $5.35M, a 41.28% decline year-over-year.
- Instil Bio, Inc. general and administrative expense for the quarter ending 2025-12-31 was $6.06M, a 41.58% decline year-over-year.
- Instil Bio, Inc. general and administrative expense for the quarter ending 2025-09-30 was $5.89M, a 44.94% decline year-over-year.
- Instil Bio, Inc. general and administrative expense for fiscal 2025 was $27.22M, a 38.43% decline from fiscal 2024.
- Instil Bio, Inc. general and administrative expense for fiscal 2024 was $44.21M, a 7.03% decline from fiscal 2023.
- Instil Bio, Inc. general and administrative expense for fiscal 2023 was $47.55M, a 23.59% decline from fiscal 2022.
- Instil Bio, Inc. general and administrative expense for fiscal 2022 was $62.23M, a 28.83% increase from fiscal 2021.
| Period end | General and Administrative Expense 3 month | General and Administrative Expense 6 month | General and Administrative Expense 9 month | General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.13M 10-Q · filed 2026-08-13 | $10.48M 10-Q · filed 2026-08-13 | $16.54M derived: sum of 3 quarters · filed 2026-08-13 | $22.43M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $5.35M 10-Q · filed 2026-05-15 | $11.41M derived: sum of 2 quarters · filed 2026-05-15 | $17.30M derived: sum of 3 quarters · filed 2026-05-15 | $23.46M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $6.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $11.96M derived: sum of 2 quarters · filed 2026-03-27 | $18.11M derived: sum of 3 quarters · filed 2026-08-13 | $27.22M 10-K · filed 2026-03-27 |
| 2025-09-30 | $5.89M 10-Q · filed 2025-11-13 | $12.05M derived: sum of 2 quarters · filed 2026-08-13 | $21.16M 10-Q · filed 2025-11-13 | $31.53M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $6.16M 10-Q · filed 2026-08-13 | $15.27M 10-Q · filed 2026-08-13 | $25.64M derived: sum of 3 quarters · filed 2026-08-13 | $36.35M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $9.11M 10-Q · filed 2026-05-15 | $19.48M derived: sum of 2 quarters · filed 2026-05-15 | $30.19M derived: sum of 3 quarters · filed 2026-05-15 | $40.90M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $10.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $21.08M derived: sum of 2 quarters · filed 2026-03-27 | $31.79M derived: sum of 3 quarters · filed 2026-03-27 | $44.21M 10-K · filed 2026-03-27 |
| 2024-09-30 | $10.71M 10-Q · filed 2025-11-13 | $21.41M derived: sum of 2 quarters · filed 2025-11-13 | $33.84M 10-Q · filed 2025-11-13 | $44.71M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $10.71M 10-Q · filed 2025-08-13 | $23.13M 10-Q · filed 2025-08-13 | $34.00M derived: sum of 3 quarters · filed 2025-08-13 | $45.94M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $12.42M 10-Q · filed 2025-05-13 | $23.30M derived: sum of 2 quarters · filed 2025-05-13 | $35.24M derived: sum of 3 quarters · filed 2025-05-13 | $46.76M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $10.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $22.81M derived: sum of 2 quarters · filed 2025-03-04 | $34.33M derived: sum of 3 quarters · filed 2025-03-04 | $47.55M 10-K · filed 2025-03-04 |
| 2023-09-30 | $11.94M 10-Q · filed 2024-11-13 | $23.46M derived: sum of 2 quarters · filed 2024-11-13 | $36.68M 10-Q · filed 2024-11-13 | $49.59M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $11.52M 10-Q · filed 2024-08-13 | $24.74M 10-Q · filed 2024-08-13 | $37.65M derived: sum of 3 quarters · filed 2024-08-13 | $54.64M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $13.22M 10-Q · filed 2024-05-10 | $26.13M derived: sum of 2 quarters · filed 2024-05-10 | $43.12M derived: sum of 3 quarters · filed 2024-05-10 | $60.34M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $12.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $29.90M derived: sum of 2 quarters · filed 2024-03-21 | $47.12M derived: sum of 3 quarters · filed 2024-03-21 | $62.23M 10-K · filed 2024-03-21 |
| 2022-09-30 | $16.99M 10-Q · filed 2023-11-13 | $34.21M derived: sum of 2 quarters · filed 2023-11-13 | $49.33M 10-Q · filed 2023-11-13 | $60.50M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $17.22M 10-Q · filed 2023-08-14 | $32.34M 10-Q · filed 2023-08-14 | $43.51M derived: sum of 3 quarters · filed 2023-08-14 | $57.47M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $15.11M 10-Q · filed 2023-05-11 | $26.29M derived: sum of 2 quarters · filed 2023-05-11 | $40.25M derived: sum of 3 quarters · filed 2023-05-11 | $54.44M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $11.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $25.14M derived: sum of 2 quarters · filed 2023-03-31 | $39.33M derived: sum of 3 quarters · filed 2023-03-31 | $48.31M 10-K · filed 2023-03-31 |
| 2021-09-30 | $13.96M 10-Q · filed 2022-11-14 | $28.16M derived: sum of 2 quarters · filed 2022-11-14 | $37.13M 10-Q · filed 2022-11-14 | $44.36M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $14.20M 10-Q · filed 2022-08-12 | $23.17M 10-Q · filed 2022-08-12 | $30.40M derived: sum of 3 quarters · filed 2022-08-12 | $33.26M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $8.98M 10-Q · filed 2022-05-16 | $16.21M derived: sum of 2 quarters · filed 2022-05-16 | $19.06M derived: sum of 3 quarters · filed 2022-05-16 | $21.46M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $7.23M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $10.09M derived: sum of 2 quarters · filed 2022-03-07 | $12.48M derived: sum of 3 quarters · filed 2022-03-07 | $14.38M 10-K · filed 2022-03-07 |
| 2020-09-30 | $2.85M 10-Q · filed 2021-11-15 | $5.25M derived: sum of 2 quarters · filed 2021-11-15 | $7.15M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $2.40M 10-Q · filed 2021-08-12 | $4.30M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $1.90M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |